Multimechanistic monoclonal antibodies (MAbs) targeting Staphylococcus aureus alpha-toxin and clumping factor A: Activity and efficacy comparisons of a MAb combination and an engineered bispecific antibody approach

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 8, 2017, Pages

  Tkaczyk, C ^a   Kasturirangan, S ^a   Minola, A ^b   Jones Nelson, O ^a   Gunter, V ^a   Shi, Y Y ^a   Rosenthal, K ^a   Aleti, V ^a   Semenova, E ^a   Warrener, P ^a   Tabor, D ^a   Stover, C K ^a   Corti, D ^b   Rainey, G ^a   Sellman, B R ^a  

^a MEDIMMUNE   (United States)

^b Humabs ^*  (Switzerland)

Author keywords

Alpha toxin; Clumping factor A; Monoclonal antibodies; Staphylococcus aureus

Indexed keywords

ALPHA TOXIN; BISPECIFIC ANTIBODY; FACTOR A; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAPHYLOCOCCUS ALPHA TOXIN; BACTERIAL TOXIN; BACTERIUM ANTIBODY; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULASE; HEMOLYSIN; NEUTRALIZING ANTIBODY; STAPHYLOCOCCAL ALPHA-TOXIN; SUVRATOXUMAB; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; BACTERIUM ISOLATE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TONSIL CELL; ANIMAL; BACTEREMIA; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECT; FEMALE; IMMUNOLOGY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PATHOGENICITY; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BACTEREMIA; BACTERIAL TOXINS; COAGULASE; FEMALE; HEMOLYSIN PROTEINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; STAPHYLOCOCCAL INFECTIONS; VIRULENCE FACTORS;

EID: 85026371963     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00629-17     Document Type: Article

References (56)

1. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.
2. DiGiandomenico A, Sellman BR. 2015. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 27:78–85. https://doi.org/10.1016/j.mib.2015.07.014.
3. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339: 520–532. https://doi.org/10.1056/NEJM199808203390806.
4. Hazenbos WL, Kajihara KK, Vandlen R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, Sai T, Sebrell A, Khalfin Y, Oh A, Koth C, Lin SJ, Lee BC, Strandh M, Koefoed K, Andersen PS, Spits H, Brown EJ, Tan MW, Mariathasan S. 2013. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 9:e1003653. https://doi.org/10.1371/journal.ppat.1003653.
5. Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jagerhofer M, Maierhofer B, Teubenbacher A, Dolezilkova I, Gross K, Banerjee S, Zauner G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Gerngross TU, Nagy E. 2015. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7:243–254. https://doi.org/10.4161/19420862.2014.985132.
6. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee Wu C S, Pham A, Zeng Z, Pons J, Rajpal A, Shelton D. 2013. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 425: 1641–1654. https://doi.org/10.1016/j.jmb.2013.02.008.
7. Karauzum H, Chen G, Abaandou L, Mahmoudieh M, Boroun AR, Shulenin S, Devi VS, Stavale E, Warfield KL, Zeitlin L, Roy CJ, Sidhu SS, Aman MJ. 2012. Synthetic human monoclonal antibodies toward staphylococcal enterotoxin B (SEB) protective against toxic shock syndrome. J Biol Chem 287:25203–25215. https://doi.org/10.1074/jbc.M112.364075.
8. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O’Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58: 1108–1117. https://doi.org/10.1128/AAC.02190-13.
9. Tkaczyk C, Hamilton MM, Sadowska A, Shi Y, Chang CS, Chowdhury P, Buonapane R, Xiao X, Warrener P, Mediavilla J, Kreiswirth B, Suzich J, Stover CK, Sellman BR. 2016. Targeting alpha toxin and ClfA with a multimechanistic monoclonal-antibody-based approach for prophylaxis of serious Staphylococcus aureus disease. mBio 7:e00528-16. https://doi.org/10.1128/mBio.00528-16.
10. DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, Bonnell J, Fleming R, Bezabeh B, Dimasi N, Sellman BR, Hilliard J, Guenther CM, Datta V, Zhao W, Gao C, Yu XQ, Suzich JA, Stover CK. 2014. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med 6:262ra155. https://doi.org/10.1126/scitranslmed.3009655.
11. Dimasi N, Gao C, Fleming C, Woods R RM, Yao XT, Shirinian L, Kiener PA, Wu H. 2009. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 393:672–692. https://doi.org/10.1016/j.jmb.2009.08.032.
12. Milstein C, Cuello AC. 1984. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 5:299–304. https://doi.org/10.1016/0167-5699(84)90155-5.
13. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD. 2010. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 23:221–228. https://doi.org/10.1093/protein/gzp077.
14. Coloma MJ, Morrison SL. 1997. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15:159–163. https://doi.org/10.1038/nbt0297-159.
15. Kontermann RE. 2012. Dual targeting strategies with bispecific antibodies. MAbs 4:182–197. https://doi.org/10.4161/mabs.4.2.19000.
16. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 7(Suppl):51–59. https://doi.org/10.4161/hv.7.0.14562.
17. Sharma-Kuinkel BK, Wu Y, Tabor DE, Mok H, Sellman BR, Jenkins A, Yu L, Jafri HS, Rude TH, Ruffin F, Schell WA, Park LP, Yan Q, Thaden JT, Messina JA, Fowler VG, Jr, Esser MT. 2015. Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia. J Clin Microbiol 53:227–236. https://doi.org/10.1128/JCM.02023-14.
18. Mendes RE, Deshpande LM, Smyth DS, Shopsin B, Farrell DJ, Jones RN. 2012. Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia. J Clin Microbiol 50: 3694–3702. https://doi.org/10.1128/JCM.02024-12.
19. Byrne H, Conroy PJ, Whisstock JC, O’Kennedy RJ. 2013. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol 31:621–632. https://doi.org/10.1016/j.tibtech.2013.08.007.
20. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205:287–294. https://doi.org/10.1084/jem.20072208.
21. Ragle BE, Bubeck Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712–2718. https://doi.org/10.1128/IAI.00115-09.
22. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. 2013. Vaccine review: “Staphyloccocus aureus vaccines: problems and prospects.” Vaccine 31:2723–2730.
23. Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, Stover CK, Sellman BR. 2015. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. mBio 6:e02272-14. https://doi.org/10.1128/mBio.02272-14.
24. Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. 2016. Antibody-based biologics and their promise to combat Staphylococcus aureus infections. Trends Pharmacol Sci 37:231–241. https://doi.org/10.1016/j.tips.2015.11.008.
25. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103:16942–16947. https://doi.org/10.1073/pnas.0606863103.
26. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202:1050–1058. https://doi.org/10.1086/656043.
27. Rauch S, DeDent AC, Kim HK, Bubeck Wardenburg J, Missiakas DM, Schneewind O. 2012. Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect Immun 80:3721–3732. https://doi.org/10.1128/IAI.00442-12.
28. Rauch S, Gough P, Kim HK, Schneewind O, Missiakas D. 2014. Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection. Infect Immun 82:4889–4898. https://doi.org/10.1128/IAI.02328-14.
29. Powers ME, Becker RE, Sailer A, Turner JR, Bubeck Wardenburg J. 2015. Synergistic action of Staphylococcus aureus alpha-toxin on platelets and myeloid lineage cells contributes to lethal sepsis. Cell Host Microbe 17:775–787. https://doi.org/10.1016/j.chom.2015.05.011.
30. Powers ME, Kim HK, Wang Y, Bubeck Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J Infect Dis 206:352–356. https://doi.org/10.1093/infdis/jis192.
31. Powers ME, Bubeck Wardenburg J. 2014. Igniting the fire: Staphylococcus aureus virulence factors in the pathogenesis of sepsis. PLoS Pathog 10:e1003871. https://doi.org/10.1371/journal.ppat.1003871.
32. Diep BA, Le VT, Visram ZC, Rouha H, Stulik L, Dip EC, Nagy G, Nagy E. 2016. Improved protection in a rabbit model of community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob Agents Chemother 60:6333–6340. https://doi.org/10.1128/AAC.01213-16.
33. Le VT, Tkaczyk C, Chau S, Rao RL, Dip EC, Pereira-Franchi EP, Cheng L, Lee S, Koelkebeck H, Hilliard JJ, Yu XQ, Datta V, Nguyen V, Weiss W, Prokai L, O’Day T, Stover CK, Sellman BR, Diep BA. 2016. Acute bacterial skin and skin structure infection: critical role of alpha-toxin and protective effects of its neutralization by a human antibody. Antimicrob Agents Chemother 60:5640–5648. https://doi.org/10.1128/AAC.00710-16.
34. Diep BA, Hilliard JJ, Le VT, Tkaczyk C, Le HN, Tran VG, Rao RL, Dip EC, Pereira-Franchi EP, Cha P, Jacobson S, Broome R, Cheng LI, Weiss W, Prokai L, Nguyen V, Stover CK, Sellman BR. 2017. Targeting alpha toxin to mitigate its lethal toxicity in ferret and rabbit models of Staphylococcus aureus necrotizing pneumonia. Antimicrob Agents Chemother 61: e02456-16. https://doi.org/10.1128/AAC.02456-16.
35. Foster TJ, Geoghegan JA, Ganesh VK, Hook M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 12:49–62. https://doi.org/10.1038/nrmicro3161.
36. McAdow M, Missiakas DM, Schneewind O. 2012. Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections. J Innate Immun 4:141–148. https://doi.org/10.1159/000333447.
37. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 7:e1002307. https://doi.org/10.1371/journal.ppat.1002307.
38. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Hook M, Degen JL. 2013. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 121:1783–1794. https://doi.org/10.1182/blood-2012-09-453894.
39. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, Foster T, Hook M. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 247:416–424. https://doi.org/10.1111/j.1432-1033.1997.00416.x.
40. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnion KM. 2010. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78:1717–1727. https://doi.org/10.1128/IAI.01065-09.
41. Hall AE, Domanski PJ, Patel PR, Vernachio JH, Syribeys PJ, Gorovits EL, Johnson MA, Ross JM, Hutchins JT, Patti JM. 2003. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect Immun 71:6864–6870. https://doi.org/10.1128/IAI.71.12.6864-6870.2003.
42. Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM. 2006. Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo. Antimicrob Agents Chemother 50:511–518. https://doi.org/10.1128/AAC.50.2.511-518.2006.
43. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260–265. https://doi.org/10.1016/j.jpeds.2007.04.060.
44. Weems JJ, Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG, Jr. 2006. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:2751–2755. https://doi.org/10.1128/AAC.00096-06.
45. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27:3276 –3280. https://doi.org/10.1016/j.vaccine.2009.01.062.
46. Brady RA, Mocca CP, Burns DL. 2013. Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants. Clin Vaccine Immunol 20:1338–1340. https://doi.org/10.1128/CVI.00275-13.
47. Rasmussen RV, Fowler VG, Jr, Skov R, Bruun NE. 2011. Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA. Future Microbiol 6:43–56. https://doi.org/10.2217/fmb.10.155.
48. Tenover FC, Tickler IA, Goering RV, Kreiswirth BN, Mediavilla JR, Persing DH, MRSA Consortium. 2012. Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States hospitals. Antimicrob Agents Chemother 56:1324 –1330. https://doi.org/10.1128/AAC.05804-11.
49. Corti D, Lanzavecchia A. 2014. Efficient methods to isolate human monoclonal antibodies from memory B cells and plasma cells. Microbiol Spectr 2:10.1128/microbiolspec.AID-0018-2014. https://doi.org/10.1128/microbiolspec.AID-0018-2014.
50. Chen W, Ying T, Dimitrov DS. 2013. Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opin Biol Ther 13:657–671. https://doi.org/10.1517/14712598.2013.761969.
51. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Jr, Aman MJ, Dye JM, Lai JR, Chandran K. 2016. A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses. Science 354:350–354. https://doi.org/10.1126/science.aag3267.
52. Laventie BJ, Rademaker HJ, Saleh M, de Boer E, Janssens R, Bourcier T, Subilia A, Marcellin L, van Haperen R, Lebbink JH, Chen T, Prevost G, Grosveld F, Drabek D. 2011. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins. Proc Natl Acad Sci U S A 108:16404–16409. https://doi.org/10.1073/pnas.1102265108.
53. Corti D, Kearns JD. 2016. Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. Curr Opin Immunol 40:51– 61. https://doi.org/10.1016/j.coi.2016.03.001.
54. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. Genome Med 6:90. https://doi.org/10.1186/s13073-014-0090-6.
55. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10:871–875. https://doi.org/10.1038/nm1080.
56. Tkaczyk C, Hua L, Varkey R, Shi Y, Dettinger L, Woods R, Barnes A, MacGill RS, Wilson S, Chowdhury P, Stover CK, Sellman BR. 2012. Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency. Clin Vaccine Immunol 19:377–385. https://doi.org/10.1128/CVI.05589-11.